Pfizer And Sangamo Start Phase III Study For Hemophilia A Gene Therapy

Giroctocogene Fitelparvovec Sustains Factor VIII Levels With No Bleeds

 
• By Kevin Grogan
  
New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
Pfizer hoping to lead hemophilia A gene therapy field • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas